Anti-Diabetic Agents

Revenex is committed to advancing healthcare through innovative and effective therapies. Our anti-diabetic portfolio addresses the diverse needs of patients managing diabetes, offering a comprehensive range of products built on proven molecules. Each therapy is designed to support optimal glycemic control and contribute to better overall health outcomes.

Our Products:

• Nexempa 10mg / 25mg – Empagliflozin, a selective SGLT2 inhibitor.
• Nexempa M500 / M1000 – Empagliflozin combined with Metformin, providing dual-action therapy.
• Nexempa L 25/5 – Empagliflozin and Linagliptin combination.
• Nexlina 5 – Linagliptin, a DPP-4 inhibitor.
• Nexlina D – Linagliptin and Metformin combination for comprehensive management.
   

Our anti-diabetic agents are formulated with a focus on efficacy, safety, and patient adherence. Revenex aims to provide healthcare professionals with reliable options to support individualized treatment plans. By leveraging advanced molecules and innovative formulations, our portfolio empowers patients and clinicians alike to achieve better management of diabetes.

Revenex continues to invest in research and development, ensuring our therapies remain at the forefront of medical innovation. Our commitment to quality and patient-centered care reinforces our position as a trusted partner in diabetes management, helping to improve patient outcomes and enhance quality of life across the communities we serve.